Liuzhou Chemical Industry (600423.SH) announced a decrease in profit forecast. It is expected that the net profit for the year 2024 will be 28.44 million yuan, a decrease of 61% compared to the previous year.
Yiuhua Group (600423.SH) announced that the company is expected to achieve a net profit attributable to the listed company shareholders in the annual report for the year 2024.
Liuzhou Chemical Industry (600423.SH) announced that it expects to achieve a net profit attributable to shareholders of the listed company of 28.44 million yuan in 2024, which is a decrease of 44.81 million yuan compared to the same period last year (according to statutory disclosure data), a year-on-year decrease of around 61%.
The main reason for the company's performance decline this time is the non-recurring gains and losses. Firstly, in the same period of the previous year, the company did not declare the debt for judicial restructuring and obtained a debt restructuring income of 45.07 million yuan; secondly, this period, the company reached a settlement in the bankruptcy debt dispute with Fujian Saneng Energy Saving Technology Co., Ltd., which is expected to reduce this period's profit by 4.8 million yuan.
In terms of the main business, the company's production facilities have achieved safe, stable, and efficient operation. The completion of the 60,000-ton/year expansion and 20,000-ton/year concentrated hydrogen peroxide projects have played a good role in this period, resulting in a significant increase in sales volume of hydrogen peroxide, a decrease in unit production cost, and a slight increase in net profit after deducting non-recurring gains and losses from the previous period.
Related Articles

Jiangsu Hengrui Pharmaceuticals (600276.SH): some drugs have obtained approval letters for clinical trials of drugs.

CSPC Pharma (01093) cancelled 25.45 million repurchased shares on May 9th.

On May 9, the Minerva Group (00397) spent approximately HK$287,800 to repurchase 4.3 million shares.
Jiangsu Hengrui Pharmaceuticals (600276.SH): some drugs have obtained approval letters for clinical trials of drugs.

CSPC Pharma (01093) cancelled 25.45 million repurchased shares on May 9th.

On May 9, the Minerva Group (00397) spent approximately HK$287,800 to repurchase 4.3 million shares.

RECOMMEND

General Administration of Customs: China's goods trade imports and exports increased by 2.4% year-on-year in the first 4 months.
09/05/2025

Key details are yet to be finalized. The market's response to the US-UK trade agreement has been lukewarm.
09/05/2025

Risk assets rebounded to boost the market, Bitcoin surged back above $100,000.
09/05/2025